Tokushima University / Educator and Researcher Directory --- Aizawa, Fuka

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Naoto Okada, Hirofumi Hamano, Kenta Yagi, Takahiro Niimura, Fuka Aizawa, Mitsuhiro Goda, Yoshito Zamami, Takashi Kitahara and Keisuke Ishizawa : Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database., International journal of clinical pharmacology and therapeutics, Vol.62, No.2, 69-76, 2024. (Summary) Although further analyses are required to confirm our findings, this study indicated that pre-treatment with EGFR-TKI might not increase the ILD risk after ICI treatment. (Keyword) Humans / Lung Neoplasms / Immune Checkpoint Inhibitors / Carcinoma, Non-Small-Cell Lung / Retrospective Studies / Japan / Lung Diseases, Interstitial / ErbB Receptors / Protein Kinase Inhibitors (Link to Publication Site) ● Publication site (DOI): 10.5414/CP204491 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37969096 ● Search Scopus @ Elsevier (PMID): 37969096 ● Search Scopus @ Elsevier (DOI): 10.5414/CP204491 (DOI: 10.5414/CP204491, PubMed: 37969096)
2.	Toshihiko Yoshioka, Mitsuhiro Goda, Masaya Kanda, Sayuri Itobayashi, Yugo Sugimoto, Yuki Izawa-Ishizawa, Kenta Yagi, Fuka Aizawa, Koji Miyata, Takahiro Niimura, Hirofumi Hamano, Takumi Sakurada, Yoshito Zamami and Keisuke Ishizawa : Valproic acid treatment attenuates cisplatin-induced kidney injury by suppressing proximal tubular cell damage., Clinical and Translational Science, Vol.16, No.11, 2369-2381, 2023. (Summary) Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods. Sodium valproic acid is a prophylactic drug candidate with a high potential for clinical application against cisplatin-induced kidney injury. Therefore, in this study, we aimed to elucidate the mechanism underlying the prophylactic effect of valproic acid on cisplatin-induced kidney injury in a mouse model and HK2 and PODO cells with cisplatin-induced toxicity. In the mouse model of cisplatin-induced kidney injury, various renal function parameters and tubular damage scores were worsened by cisplatin, but they were significantly improved upon combination with valproic acid. No difference was observed in cisplatin accumulation between the cisplatin-treated and valproic acid-treated groups in whole blood and the kidneys. The mRNA expression levels of proximal tubular damage markers, apoptosis markers, and inflammatory cytokines significantly increased in the cisplatin group 72 h after cisplatin administration but significantly decreased upon combination with valproic acid. In HK2 cells, a human proximal tubular cell line, the cisplatin-induced decrease in cell viability was significantly suppressed by co-treatment with valproic acid. Valproic acid may inhibit cisplatin-induced kidney injury by suppressing apoptosis, inflammatory responses, and glomerular damage throughout the kidneys by suppressing proximal tubular cell damage. However, prospective controlled trials need to evaluate these findings before their practical application. (Keyword) Mice / Animals / Humans / Cisplatin / Valproic Acid / Prospective Studies / Acute Kidney Injury / Kidney / Apoptosis / Mice, Inbred C57BL (Link to Publication Site) ● Publication site (DOI): 10.1111/cts.13638 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37700528 ● Search Scopus @ Elsevier (PMID): 37700528 ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13638 (DOI: 10.1111/cts.13638, PubMed: 37700528)
3.	Kaito Tsujinaka, Yuki Izawa-Ishizawa, Koji Miyata, Toshihiko Yoshioka, Kohei Oomine, Honoka Nishi, Masateru Kondo, Syuto Itokazu, Tatsumi Miyata, Takahiro Niimura, Maki Sato, Fuka Aizawa, Kenta Yagi, Masayuki Chuma, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection., Biomedicine & Pharmacotherapy, Vol.167, 2023. (Summary) Aortic dissection is an adverse event of angiogenesis inhibitors; however, the association between the drugs and aortic dissection is unclear. Therefore, we investigated if and how angiogenesis inhibitors increase the onset of aortic dissection using pharmacologically-induced aortic dissection-prone model (LAB) mice, cultured endothelial cells, and real-world databases, which is a novel integrated research approach. Disproportionality analysis was performed and calculated using the reporting odds ratio as a risk signal using a worldwide database of spontaneous adverse events to estimate the risk of adverse events. Angiogenesis inhibitors, but not other hypertension-inducing drugs, showed significant risk signals for aortic aneurysms and dissection. A retrospective cohort analysis using JMDC, a medical receipt database in Japan, showed that the history of atherosclerosis and dyslipidemia, but not hypertension, were significantly associated with the onset of aortic dissection during angiogenesis inhibitor medication administration. For in vivo studies, sunitinib (100 mg/kg/day) was administered to LAB mice. Sunitinib increased systolic blood pressure (182 mmHg vs. 288 mmHg with sunitinib; p<0.01) and the incidence of aortic dissection (40% vs. 59% with sunitinib; p = 0.34) in mice. In vivo and in vitro studies revealed that sunitinib increased endothelin-1 expression and induced endothelial cell damage evaluated by intracellular- and vascular cell adhesion molecule-1 expressions. The increased risk of developing aortic dissection with angiogenesis inhibitors is associated with the development of drug-specific hypertension via endothelial cell damage and endothelin-1 expression. Our findings are invaluable in establishing safer anticancer therapies and strategies to prevent the development of vascular toxicity in high-risk patients. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.biopha.2023.115504 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37722188 ● Search Scopus @ Elsevier (PMID): 37722188 ● Search Scopus @ Elsevier (DOI): 10.1016/j.biopha.2023.115504 (DOI: 10.1016/j.biopha.2023.115504, PubMed: 37722188)
4.	Takahiro Niimura, Koji Miyata, Hirofumi Hamano, Yuuki Nounin, Hiroto Unten, Masaki Yoshino, Satoru Mitsuboshi, Fuka Aizawa, Kenta Yagi, Toshihiro Koyama, Mitsuhiro Goda, Yasunari Kanda, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : Cardiovascular Toxicities Associated with Anaplastic Lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase)., Drug Safety, 2023. (Summary) Systematic evaluation of ALK inhibitor-associated adverse events revealed differences in the cardiotoxicity profiles among ALK inhibitors. Understanding the differences in the cardiovascular toxicity profile of each ALK inhibitor will contribute to safe drug therapy when switching between ALK inhibitors. (Link to Publication Site) ● Publication site (DOI): 10.1007/s40264-023-01300-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37106270 ● Search Scopus @ Elsevier (PMID): 37106270 ● Search Scopus @ Elsevier (DOI): 10.1007/s40264-023-01300-9 (DOI: 10.1007/s40264-023-01300-9, PubMed: 37106270)
5.	Kenta Yagi, Akinori Maruo, Shunsuke Ishida, Fuka Aizawa, Soichiro Ushio, Satoshi Sakaguchi, Makoto Kajizono, Takahiro Niimura, Mitsuhiro Goda, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study., Clinical and Experimental Medicine, 2023. (Summary) Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether the use of PPIs or vonoprazan in patients with cancer receiving bevacizumab affected the duration of bevacizumab treatment. This observational study was conducted at two national university hospitals in Japan and involved 222 patients using oral PPIs (N = 190) or vonoprazan (N = 32) at the start of bevacizumab treatment between January 2015 and December 2018. Patients who received only one course of bevacizumab were excluded. The primary endpoint was the duration of bevacizumab treatment. The duration of bevacizumab treatment varied significantly between the PPI and vonoprazan groups. For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (p < 0.05) and was longer in the vonoprazan group than in the PPI group. However, for colorectal cancer, the median duration of bevacizumab treatment was 147 days longer in the PPI group than in the vonoprazan group. Selection of appropriate gastric acid secretion inhibitors may improve the therapeutic efficacy of anti-VEGF drugs, including bevacizumab. Oestrogen is a key regulator of this effect and may be responsible for the varying association between PPI or vonoprazan administration and the difference in bevacizumab treatment duration between colon cancer and other cancer types. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10238-023-01008-1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36738305 ● Search Scopus @ Elsevier (PMID): 36738305 ● Search Scopus @ Elsevier (DOI): 10.1007/s10238-023-01008-1 (DOI: 10.1007/s10238-023-01008-1, PubMed: 36738305)
6.	Takahiro Niimura, Yoshito Zamami, Koji Miyata, Takahisa Mikami, Mizuho Asada, Keijo Fukushima, Masaki Yoshino, Satoru Mitsuboshi, Naoto Okada, Hirofumi Hamano, Takumi Sakurada, Rie Matsuoka-Ando, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Masayuki Chuma, Toshihiro Koyama, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Hiromichi Fujino, Yoshihiro Yamanishi and Keisuke Ishizawa : Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System., Journal of Clinical Pharmacology, Vol.63, No.4, 473-479, 2022. (Summary) Myasthenia gravis (MG) is a rare but fatal adverse event of immune checkpoint inhibitors (ICIs). We assessed whether patient characteristics differed between those with ICI-related myasthenia gravis and those with idiopathic myasthenia gravis. Reports from the US Food and Drug Administration Adverse Event Reporting System were analyzed. Multivariate analyses were conducted to evaluate the associations between age, sex, and ICI treatment and the reporting rate of myasthenia gravis. Among 5 464 099 cases between 2011 and 2019, 53 447 were treated with ICIs. Myasthenia gravis was reported more often in ICI users. Multiple logistic regression analyses showed that the reporting rate of ICI-related myasthenia gravis did not differ significantly between men and women; however, it was higher in older people than in younger people (adjusted odds ratio, 2.4 [95%CI, 1.84-3.13]). We also investigated useful signs for the early detection of myositis and myocarditis, which are fatal when overlapping with ICI-related myasthenia gravis. Patients with elevated serum creatine kinase or troponin levels were more likely to have concurrent myositis and myocarditis. Unlike idiopathic myasthenia gravis, there was no sex difference in the development of ICI-related myasthenia gravis, which may be more common in older people. Considering the physiological muscle weakness that occurs in the elderly, it may be necessary to monitor ICI-related myasthenia gravis more closely in older people. (Keyword) Male / United States / Humans / Female / Aged / Immune Checkpoint Inhibitors / United States Food and Drug Administration / Myocarditis / Myasthenia Gravis / Myositis (Link to Publication Site) ● Publication site (DOI): 10.1002/jcph.2187 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36453166 ● Search Scopus @ Elsevier (PMID): 36453166 ● Search Scopus @ Elsevier (DOI): 10.1002/jcph.2187 (DOI: 10.1002/jcph.2187, PubMed: 36453166)
7.	Rie Ando-Matsuoka, Kenta Yagi, Mayu Takaoka, Yuko Sakajiri, Tomokazu Shibata, Ryusuke Sawada, Akinori Maruo, Koji Miyata, Fuka Aizawa, Hirofumi Hamano, Takahiro Niimura, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Satoshi Sakaguchi, Yoshito Zamami, Yoshihiro Yamanishi and Keisuke Ishizawa : Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells., Drug Development Research, Vol.84, No.1, 75-83, 2022. (Summary) Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion, used as first-line agents in treating peptic ulcers. However, we have previously reported that PPIs may diminish the therapeutic effect of anti-vascular endothelial growth factor (VEGF) drugs in patients with cancer. In this study, we explored the effects of vonoprazan, a novel gastric acid secretion inhibitor used for the treatment of peptic ulcers, on the secretion of VEGF in cancer cells and attempted to propose it as an alternative PPI for cancer chemotherapy. The effects of PPI and vonoprazan on VEGF expression in cancer cells were compared by real-time reverse transcription-polymerase chain reaction and ELISA. The interaction of vonoprazan and PPIs with transcriptional regulators by docking simulation analysis. In various cancer cell lines, including the human colorectal cancer cell line (LS174T), PPI increased VEGF messenger RNA expression and VEGF protein secretion, while this effect was not observed with vonoprazan. Molecular docking simulation analysis showed that vonoprazan had a lower binding affinity for estrogen receptor alpha (ER-α), one of the transcriptional regulators of VEGF, compared to PPI. Although the PPI-induced increase in VEGF expression was counteracted by pharmacological ER-α inhibition, the effect of vonoprazan on VEGF expression was unchanged. Vonoprazan does not affect VEGF expression in cancer cells, which suggests that vonoprazan might be an alternative to PPIs, with no interference with the therapeutic effects of anti-VEGF cancer chemotherapy. (Keyword) Humans / Proton Pump Inhibitors / Endothelial Growth Factors / Molecular Docking Simulation / Peptic Ulcer / Pyrroles / Neoplasms (Tokushima University Institutional Repository) ● Metadata: 118289 (Link to Publication Site) ● Publication site (DOI): 10.1002/ddr.22013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36484282 ● Search Scopus @ Elsevier (PMID): 36484282 ● Search Scopus @ Elsevier (DOI): 10.1002/ddr.22013 (Tokushima University Institutional Repository: 118289, DOI: 10.1002/ddr.22013, PubMed: 36484282)
8.	Takumi Sakurada, Hiroshi Nokihara, Tadashi Koga, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Fuka Aizawa, Hirokazu Ogino, Seidai Satou, Yasushi Kirino, Hisatsugu Goto, Yasuhiko Nishioka and Keisuke Ishizawa : Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study., The Oncologist, Vol.27, No.7, e554-e560, 2022. (Summary) Prophylactic administration of low-dose dexamethasone for 5 days from the day after pemetrexed administration resulted in a milder incidence and severity of rash. These findings may provide a standard preventative strategy for pemetrexed-induced rashes. (Trial identifier: UMIN000025666). (Keyword) Adrenal Cortex Hormones / Carcinoma, Non-Small-Cell Lung / Cisplatin / Dexamethasone / Exanthema / Humans / Lung Neoplasms / Mesothelioma, Malignant / Pemetrexed (Tokushima University Institutional Repository) ● Metadata: 117391 (Link to Publication Site) ● Publication site (DOI): 10.1093/oncolo/oyab077 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35325241 ● Search Scopus @ Elsevier (PMID): 35325241 ● Search Scopus @ Elsevier (DOI): 10.1093/oncolo/oyab077 (Tokushima University Institutional Repository: 117391, DOI: 10.1093/oncolo/oyab077, PubMed: 35325241)
9.	Shiori Nishiuchi, Kenta Yagi, Hiroumi Saito, Yoshito Zamami, Takahiro Niimura, Koji Miyata, Yoshika Sakamoto, Kimiko Fukunaga, Shunsuke Ishida, Hirofumi Hamano, Fuka Aizawa, Mitsuhiro Goda, Masayuki Chuma, Yuki Izawa-Ishizawa, Hideki Nawa, Hiroaki Yanagawa, Yasunari Kanda and Keisuke Ishizawa : Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis., European Journal of Pharmacology, Vol.928, No.175083, 2022. (Summary) These findings suggest that doxorubicin-induced cardiac events are suppressed by the administration of mosapride and sirolimus. (Keyword) Animals / apoptosis / Cardiotoxicity / data analysis / Doxorubicin / Mice / Myocytes, Cardiac / Pharmaceutical Preparations / RNA, Messenger / Sirolimus (Tokushima University Institutional Repository) ● Metadata: 117365 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejphar.2022.175083 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35659512 ● Search Scopus @ Elsevier (PMID): 35659512 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejphar.2022.175083 (Tokushima University Institutional Repository: 117365, DOI: 10.1016/j.ejphar.2022.175083, PubMed: 35659512)
10.	Masaya Kanda, Mitsuhiro Goda, Akiko Maegawa, Toshihiko Yoshioka, Ami Yoshida, Koji Miyata, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Takumi Sakurada, Masayuki Chuma, Kenta Yagi, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Yoshito Zamami and Keisuke Ishizawa : Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis., Clinical and Translational Science, Vol.15, No.7, 1664-1675, 2022. (Summary) Cisplatin is effective against many types of carcinoma. However, a high rate of renal damage is a clinical problem. Thus, there is a need to establish a method to prevent it. Although various compounds have been reported to be effective against cisplatin-induced renal injury, there are no examples of their clinical application. Therefore, we attempted to search for prophylactic agents with a high potential for clinical application. We used Cascade Eye to identify genes that are altered during cisplatin-induced renal injury, Library of Integrated Network-based Cellular Signatures (LINCS) to identify drugs that inhibit changes in gene expression, and a large database of spontaneous adverse drug reaction reports to identify drugs that could prevent cisplatin-induced kidney injury in clinical practice. In total, 10 candidate drugs were identified. Using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), we identified drugs that reduce cisplatin-induced kidney injury. Fenofibrate was selected as a candidate drug to prevent cisplatin-induced kidney injury based on the FAERS analysis. A model was used to evaluate the efficacy of fenofibrate against cisplatin-induced renal injury. Studies using HK2 cells and mouse models showed that fenofibrate significantly inhibited cisplatin-induced renal injury but did not inhibit the antitumor effect of cisplatin. Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin-induced renal injury. Analysis of data from multiple big databases will improve the search for novel prophylactic drugs with high clinical applicability. For the practical application of these findings, evaluation in prospective controlled trials is necessary. (Keyword) Acute Kidney Injury / Animals / Cisplatin / data analysis / Fenofibrate / kidney disease / Mice / Prospective Studies (Tokushima University Institutional Repository) ● Metadata: 117366 (Link to Publication Site) ● Publication site (DOI): 10.1111/cts.13282 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35445533 ● Search Scopus @ Elsevier (PMID): 35445533 ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13282 (Tokushima University Institutional Repository: 117366, DOI: 10.1111/cts.13282, PubMed: 35445533)
11.	Kenta Yagi, Yasutaka Sato, Satoshi Sakaguchi, Mitsuhiro Goda, Hirofumi Hamano, Fuka Aizawa, Mayuko Shimizu, Arisa Inoue-Hamano, Toshihide Nishimori, Masato Tagi, Marina Kanno, Rie Matsuoka-Ando, Toshihiko Yoshioka, Yoshiko Matstubara, Yuki Izawa-Ishizawa, Rieko Shimizu, Akinori Maruo, Yurika Kuniki, Yoshika Sakamoto, Sayuri Itobayashi, Yoshito Zamami, Hiroaki Yanagawa and Keisuke Ishizawa : A web-based survey of educational opportunities of medical professionals based on changes in conference design during the COVID-19 pandemic., Education and Information Technologies, Vol.27, 10371-10386, 2022. (Summary) The online version contains supplementary material available at 10.1007/s10639-022-11032-5. (Link to Publication Site) ● Publication site (DOI): 10.1007/s10639-022-11032-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35464114 ● Search Scopus @ Elsevier (PMID): 35464114 ● Search Scopus @ Elsevier (DOI): 10.1007/s10639-022-11032-5 (DOI: 10.1007/s10639-022-11032-5, PubMed: 35464114)
12.	Yoshito Zamami, Takahiro Niimura, Takehiro Kawashiri, Mitsuhiro Goda, Yutaro Naito, Keijo Fukushima, Soichiro Ushio, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Koji Miyata, Kenshi Takechi, Masayuki Chuma, Toshihiro Koyama, Daisuke Kobayashi, Takao Shimazoe, Hiromichi Fujino, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data., Biomedicine & Pharmacotherapy, Vol.148, 2022. (Summary) Thus, drug repositioning using data from large-scale basic and clinical databases enables the discovery of new indications for approved drugs with a high probability of success. (Keyword) Animals / Anticholesteremic Agents / Antineoplastic Agents / Big Data / Databases, Factual / Drug Repositioning / Humans / Hyperalgesia / Japan / Male / Mice / Mice, Inbred BALB C / Oxaliplatin / Peripheral Nervous System Diseases / Pre-Exposure Prophylaxis / Rats / Rats, Sprague-Dawley / Retrospective Studies / Simvastatin (Tokushima University Institutional Repository) ● Metadata: 117414 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.biopha.2022.112744 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35240525 ● Search Scopus @ Elsevier (PMID): 35240525 ● Search Scopus @ Elsevier (DOI): 10.1016/j.biopha.2022.112744 (Tokushima University Institutional Repository: 117414, DOI: 10.1016/j.biopha.2022.112744, PubMed: 35240525)
13.	Naoto Okada, Yuki Izumi, Aki Nakamoto, Masayuki Chuma, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa : Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study., Clinical Therapeutics, Vol.43, No.11, 1910-1920.e3, 2021. (Summary) VIN risk was higher with VT than with VC, even when the AUC was controlled to the guideline-recommended range. These results strongly suggest that VIN prevention may be difficult with AUC-guided vancomycin dosing in patients receiving VT. (Keyword) Acute Kidney Injury / Anti-Bacterial Agents / Bayes Theorem / Cefepime / Drug Therapy, Combination / Humans / Penicillanic Acid / Piperacillin / Piperacillin, Tazobactam Drug Combination / Prevalence / Retrospective Studies / Vancomycin (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clinthera.2021.09.007 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34642081 ● Search Scopus @ Elsevier (PMID): 34642081 ● Search Scopus @ Elsevier (DOI): 10.1016/j.clinthera.2021.09.007 (DOI: 10.1016/j.clinthera.2021.09.007, PubMed: 34642081)
14.	Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Ami Yoshida, Yoichi Murai, Yoshito Zamami, Fuka Aizawa, Takahiro Niimura, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Masayuki Chuma, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Effects of 5-HT₃ receptor antagonists on cisplatin-induced kidney injury., Clinical and Translational Science, 2021. (Summary) receptor antagonists do not worsen cisplatin-induced acute kidney injury. The findings should be validated in a prospective controlled trial before implementation in clinical practice. (Tokushima University Institutional Repository) ● Metadata: 116008 (Link to Publication Site) ● Publication site (DOI): 10.1111/cts.13045 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33982438 ● Search Scopus @ Elsevier (PMID): 33982438 ● Search Scopus @ Elsevier (DOI): 10.1111/cts.13045 (Tokushima University Institutional Repository: 116008, DOI: 10.1111/cts.13045, PubMed: 33982438)
15.	Yuki Izawa-Ishizawa, Mitsuhiro Goda, Fuka Aizawa, Yoshito Zamami, Hirofumi Hamano, Kenta Yagi, Yasumasa Ikeda, Keisuke Ishizawa and Toshiaki Tamaki : 薬剤誘発性大動脈解離易発症モデルマウスを用いた薬効評価, Shikoku Acta Medica, Vol.77, No.1,2, 57-62, 2021. (Summary) Aortic dissection (or dissecting aortic aneurysm) is a condition in which the aortic wall is separated into two layers at the medial level to form a pseudocavity. The intima crack, called the ``entry'', allows blood to tear through the medial layer and flow in. The location of the ``entry'' and the extent of the dissection can cause a variety of serious complications, including rupture, cardiac tamponade, and obstruction of branched vessels. According to the Guideline on Diagnosis and Treatment of Aortic Aneurysm and Aortic Dissection 2020, it is estimated that 61.4% of the onset of dissection die before arrival at the hospital, and 93% will die within 24 hours after the onset. It has been suggested that the morbidity rate has been increasing in recent years. Since many of them have a fatal prognosis, it is an important issue to prevent the onset itself. However, no effective therapeutic agent or preventive strategy has been established so far. The first reason is that it is extremely difficult to design clinical studies because aortic dissection traced the rapid onset and progression. The second is that the pathophysiology and preventive drug search are not sufficiently conducted even at the basic research level. Epidemiologically, the results of the International Registry of Aortic Dissection (IRAD) revealed that aging, hypertension, atherosclerosis, and hereditary connective tissue diseases are risk factors. The aortic aneurysm also shows similar pathological conditions caused by these risk factors. However, one of the major differences between aneurysm and dissection is the presence of aortic intima rupture. Therefore, we attempted to establish a mouse model developing dissection at a high rate by adding the endothelial dysfunction to a pharmacologically induced aortic aneurysm model mouse. Furthermore, we evaluated the efficacy of pitavastatin and several nutrients using our novel model mice and verified its usefulness as a model animal. (Keyword) aortic dissection / endothelial dysfunction / statin / polyphenol / large medical databases (Tokushima University Institutional Repository) ● Metadata: 116038 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050851320431028352 (Tokushima University Institutional Repository: 116038, CiNii: 1050851320431028352)

Academic Letter:

1.	Satoru Mitsuboshi, Takahiro Niimura, Fuka Aizawa, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database., Basic & Clinical Pharmacology & Toxicology, Vol.130, No.4, 553-556, 2022. (Keyword) Adrenergic beta-Antagonists / Atenolol / Drug-Related Side Effects and Adverse Reactions / Female / Humans / Hypertension / Japan / Male / Renal Insufficiency, Chronic (Link to Publication Site) ● Publication site (DOI): 10.1111/bcpt.13717 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35174631 ● Search Scopus @ Elsevier (PMID): 35174631 ● Search Scopus @ Elsevier (DOI): 10.1111/bcpt.13717 (DOI: 10.1111/bcpt.13717, PubMed: 35174631)

Review, Commentary:

1.	Yoshito Zamami, Hirofumi Hamano, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Drug-Repositioning Approaches Based on Medical and Life Science Databases., Frontiers in Pharmacology, Vol.12, No.752174, Nov. 2021. (Tokushima University Institutional Repository) ● Metadata: 116895 (Link to Publication Site) ● Publication site (DOI): 10.3389/fphar.2021.752174 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3389/fphar.2021.752174 (Tokushima University Institutional Repository: 116895, DOI: 10.3389/fphar.2021.752174)

Proceeding of International Conference:

1.	Takahiro Niimura, Koji Miyata, Kenta Yagi, Fuka Aizawa, Kei Kawada, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Evaluation of cardiovascular toxicity profile of ALK inhibitors using adverse event reporting database., ASCPT 2024 Annual Meeting Colorado Springs March 2024, Colorado Springs, Mar. 2024.
2.	Koji Miyata, Yuki Izawa-Ishizawa, Honoka Nishi, Shuto Itokazu, Tatsumi Miyata, Kaito Tsujinaka, Masateru Kondo, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : Fluoroquinolones attribute aortic diseases through endothelial dysfunction., ASCPT 2024 Annual Meeting, Colorado Springs, Mar. 2024.
3.	Kei Kawada, Ishida Tomoaki, Morisawa Shumpei, Jobu Kohei, Higasi Youichirou, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : Atractylodes lancea Rhizome-derived Exosome-like Nanoparticles Suppress Lipopolysaccharide-induced Inflammation in Murine Microglial Cells, 81st FIP World Congress of Pharmacy and Pharmaceutical Sciences., Brisbane, Sep. 2023.
4.	Mitsuhiro Goda, Kanda Masaya, Yoshioka Toshihiko, Miyata Koji, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Sakurada Takumi and Yuki Izawa-Ishizawa : Discovery of preventive drugs for cisplatin-induced acute kidney injury., 19th World Congress of Basic & Clinical Pharmacology (WCP2023), Glasgow, Jul. 2023.
5.	Miyata Koji, Yuki Izawa-Ishizawa, Takahiro Niimura, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : Investigation of PDE5 Inhibitors and Artery Diseases Using Real-World Database, 19th World Congress of Basic & Clinical Pharmacology (WCP2023), Glasgow, Jul. 2023.

Proceeding of Domestic Conference:

1.	Kenta Yagi, Sayaka Imawaka, Mayu Takaoka, Naoki Okamoto, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Kei Kawada, Yuki Izawa-Ishizawa and Keisuke Ishizawa : Bcr-Abl 阻害剤に対する慢性骨髄性白血病細胞の耐性獲得メカニズムの探索, 第144回日本薬理学会近畿部会, Mar. 2024.
2.	Yuki Izawa-Ishizawa, Koji Miyata, Kaito Tsujinaka, Shuto Itokazu, Tatsumi Miyata, Masateru Kondoh, Takahiro Niimura, Toshihiko Yoshioka, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬による大動脈疾患リスクに関する2つの矛盾, 第144回日本薬理学会近畿部会, Mar. 2024.
3.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, Kenta Yagi, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa, Kei Kawada and Keisuke Ishizawa : HMG-CoA還元酵素阻害剤はGST を介して抗がん剤誘発性機械的刺激応答閾値低下を改善する, 第144回日本薬理学会近畿部会, Mar. 2024.
4.	Tatsumi Miyata, Yuki Izawa-Ishizawa, Koji Miyata, Shuto Itokazu, Kaito Tsujinaka, Himeno Fukuoka, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : レボフロキサシンの血管炎症への影響, 第268回徳島医学会, Mar. 2024.
5.	Shuto Itokazu, Yuki Izawa-Ishizawa, Koji Miyata, Tatsumi Miyata, Masateru Kondoh, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : 杜仲葉エキスによる大動脈疾患発症抑制効果の検討, 第268回徳島医学会, Mar. 2024.
6.	Koji Miyata, Yuki Izawa-Ishizawa, Honoka Nishi, Shuto Itokazu, Tatsumi Miyata, Kaito Tsujinaka, Masateru Kondoh, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Kei Kawada, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬に関連した大動脈瘤解離には内皮障害が関与する, 第97回日本薬理学会年会第44回日本臨床薬理学会学術総会, Dec. 2023.
7.	Kei Kawada, 石田智滉, 福田仁, 兵頭勇己, 浜田知幸, 久保亨, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Mitsuhiro Goda and Keisuke Ishizawa : 機械学習解析を用いた心不全治療薬の年齢別有効性の検討―高知急性非代償性心不全レジストリ研究より―, 第97回日本薬理学会年会第44回日本臨床薬理学会学術総会, Dec. 2023.
8.	杉本祐悟, Mitsuhiro Goda, 石田朋奈, 加納菜々, Masaya Kanda, Toshihiko Yoshioka, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Kei Kawada, Yuki Izawa-Ishizawa and Keisuke Ishizawa : SGLT2阻害薬によるシスプラチン誘発腎障害の抑制効果, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
9.	Kenta Yagi, Takahiro Niimura, Satoshi Sakaguchi, Fuka Aizawa, Kei Kawada, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : リアルワールドデータの医療への活用に向けて, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
10.	神農麻里奈, 小川敦, 鈴木加奈, 萱野純史, Masaya Kanda, Kaito Tsujinaka, Takashi Bandoh, Ayaka Nitta, 椋田千晶, Fuka Aizawa, Kei Kawada, 櫻田巧, 桐野靖, Mitsuhiro Goda and Keisuke Ishizawa : 処方提案受容率向上を目指した栄養輸液設計ツールの検討, 第62回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2023.
11.	Kei Kawada, 石田智滉, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来細胞外膜小胞を用いた抗神経炎症治療薬の開発, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
12.	Kei Kawada, 石田智滉, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来細胞外膜小胞を用いた抗神経炎症治療薬の開発, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
13.	Toshihiko Yoshioka, Mitsuhiro Goda, Tomona Ishida, Yugo Sugimoto, 神田将哉, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの予防効果, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
14.	Yugo Sugimoto, Mitsuhiro Goda, Tomona Ishida, 加納菜々, 神田将哉, Toshihiko Yoshioka, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 慢性骨髄性白血病の薬剤耐性に有用な薬剤の探索, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
15.	友近七海, Fuka Aizawa, SONODA Yuhei, NISHIBASHI Ayaka, MIYAUCHI Kanaho, Mitsuhiro Goda, Kenta Yagi, Takahiro Niimura, Yuki Izawa-Ishizawa, 朝田瑞穂, 植沢芳広 and Keisuke Ishizawa : 実験的多発性硬化症モデルマウスに対するウルソデオキシコール酸の治療効果の検討, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
16.	Honoka Nishi, Fuka Aizawa, Yuki Izawa-Ishizawa, TSUJINAKA Kaito, MIYATA Koji, Toshihiko Yoshioka, Masateru Kondoh, Shuto Itokazu, MIYATA Tatsumi, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : 血管新生阻害剤による大動脈解離発症のリスク因子解明, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
17.	森山大嗣, Fuka Aizawa, Ami Okabayashi, Mitsuhiro Goda, Kenta Yagi, Takahiro Niimura, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 抗がん剤誘発性末梢神経障害に対するスタチン系薬剤の有効性ならびに作用標的の検討, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
18.	Kazushi Uchida, Hiroto Unten, Hirofumi Hamano, Takahiro Niimura, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 免疫チェックポイント阻害剤関連心筋炎モデルマウスの作製とモデルマウスを用いた予防薬探索, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
19.	Takahiro Niimura, MIYATA Koji, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : 有害事象報告データベースを活用したALK阻害薬の心血管毒性プロファイル解明, 生体機能と創薬シンポジウム2023, Aug. 2023.
20.	Toshihiko Yoshioka, Mitsuhiro Goda, Yugo Sugimoto, Tomona Ishida, 神田将哉, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの予防効果, 生体機能と創薬シンポジウム2023, Aug. 2023.
21.	BANDO Hiroshi, Mitsuhiro Goda, Takahiro Niimura, 新田侑生, Masayuki Chuma, 北川航平, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, 櫻田巧 and Keisuke Ishizawa : 大規模医療情報データベース解析を基盤としたラモトリギンの皮膚障害発現リスクに影響する薬剤の探索, 生体機能と創薬シンポジウム2023, Aug. 2023.
22.	Toshihiko Yoshioka, Mitsuhiro Goda, 神田将哉, Yugo Sugimoto, Yuki Izawa-Ishizawa, Kenta Yagi, Fuka Aizawa, MIYATA Koji, Takahiro Niimura, 櫻田巧, 桐野靖 and Keisuke Ishizawa : バルプロ酸ナトリウムのシスプラチン誘発腎障害予防薬としての可能性, 第267回徳島医学会学術集会, Aug. 2023.
23.	神田将哉, Mitsuhiro Goda, 吉岡俊彦, Yugo Sugimoto, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : MATE型輸送体を標的とするシスプラチン誘発腎障害予防戦略の開発, 第32回霧島神経薬理フォーラム, Aug. 2023.
24.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, Kenta Yagi, Mitsuhiro Goda, Takahiro Niimura, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 抗がん剤誘発性末梢神経障害に対するHMG-CoA還元酵素阻害剤の多面的作用, 第2回あべの薬理学懇話会, Aug. 2023.
25.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, Kenta Yagi, 高橋志門, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : スタチンはOxaliplatin および Paclitaxel 誘発性末梢神経障害を改善する, 医療薬学フォーラム2023 / 第31回クリニカルファーマシーシンポジウム, Jul. 2023.
26.	Kei Kawada, 石田智滉, 常風興平, 森沢惇平, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Takahiro Niimura, Shinji Abe, Mitsuhiro Goda and Keisuke Ishizawa : 植物由来Exosome-like Nanoparticles (ELNs)の医療への応用 -蒼朮由来ELNsによる抗神経炎症作用の検討-, 第143回日本薬理学会近畿部会, Jun. 2023.
27.	OKAMOTO Naoki, Kenta Yagi, Sayaka Imawaka, Mayu Takaoka, Yurika Kuniki, Yuki Izawa-Ishizawa, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda and Keisuke Ishizawa : 慢性骨髄性白血病に対する新規分子標的治療薬の耐性メカニズムの探索, 第143回日本薬理学会近畿部会, Jun. 2023.
28.	Yoshika Sakamoto, Nanami Tomochika, Takahiro Niimura, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : スニチニブ誘発心毒性に対する新規予防薬の探索と作用機序の検討, 日本医療薬学会第6回フレッシャーズ・カンファランス, Jun. 2023.
29.	Hiroto Unten, Kazushi Uchida, Hirofumi Hamano, Takahiro Niimura, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 免疫チェックポイント阻害剤関連心筋炎モデルマウスの確立と病理組織像の評価, 日本医療薬学会第6回フレッシャーズ・カンファランス, Jun. 2023.
30.	Kenta Yagi, Mayu Takaoka, 吉武愛哉, 丸尾陽成, Rie Andou, Fuka Aizawa, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : プロトンポンプ阻害剤およびボノプラザンがVEGF発現に与える影響, 日本薬学会第143年会, Mar. 2023.
31.	Fuka Aizawa, 岡林亜美, Daishi Moriyama, Kenta Yagi, Mitsuhiro Goda, NITTA Ayaka, Takahiro Niimura, 石澤有紀 and 石澤啓介 : 抗がん剤誘発性末梢神経障害克服に向けたスタチン系薬剤による有効性検討, 日本薬学会第143年会, Mar. 2023.
32.	Mitsuhiro Goda, 糸林小友理, 神田将哉, 吉岡俊彦, 杉本祐悟, 石田朋奈, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa, Takumi Sakurada, 桐野靖 and Keisuke Ishizawa : バルプロ酸ナトリウムのシスプラチン誘発腎障害に対する予防効果の作用機序解明, 日本薬学会第143年会, Mar. 2023.
33.	Takahiro Niimura, Hiroto Unten, Hirofumi Hamano, Kazushi Uchida, Nanami Tomochika, MIYATA Koji, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 遺伝子改変マウスを用いた免疫チェックポイント阻害剤関連心筋炎の病態モデル開発, 日本薬学会第143年会, Mar. 2023.
34.	MIYATA Koji, Yuki Izawa-Ishizawa, Hirofumi Hamano, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : ホスホジエステラーゼ5阻害剤に関連した動脈疾患, 日本薬学会第143年会, Mar. 2023.
35.	Fuka Aizawa, Kenta Yagi, Takahiro Niimura, Mitsuhiro Goda, Yoshito Zamami, Yuki Izawa-Ishizawa and Keisuke Ishizawa : データサイエンス×基礎によるCIPN支持療法薬の創出, 日本薬学会第143年会, Jan. 2023.
36.	Takahiro Niimura, Hiroto Unten, Hirofumi Hamano, Kazushi Uchida, MIYATA Koji, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and 石澤啓介 : PD-1ノックアウトマウスを用いた免疫チェックポイント阻害剤関連心筋炎の新規病態モデル開発, 第32回日本循環薬理学会, Jan. 2023.
37.	八木健太, Fuka Aizawa, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : VEGF発現にプロトンポンプ阻害剤が与える影響, 第32回日本循環薬理学会, Jan. 2023.
38.	Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Fuka Aizawa, 櫻田巧, 小川敦, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : がん薬物療法に伴う腎障害とその予防, 第96回日本薬理学会年会/第43回日本臨床薬理学学術総会シンポジウム6, Nov. 2022.
39.	Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Takahiro Niimura, 櫻田巧, 小川敦, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータ解析と基礎研究を融合した研究手法によるハイブリッド創薬, 第96回日本薬理学会年会/第43回日本臨床薬理学学術総会日本臨床薬理学会共催シンポジウム(シンポジウム41), Nov. 2022.
40.	Naoto Okada, Shingen Nakamura, Taro Shimizu, Hidenori ANDO, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Tatsuhiro Ishida and Keisuke Ishizawa : 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に関連する因子の検討, 第32回日本医療薬学学会, Sep. 2022.
41.	Naoto Okada, Shingen Nakamura, Taro Shimizu, Hidenori ANDO, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Tatsuhiro Ishida and Keisuke Ishizawa : 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に影響を与える因子の検討, 第32回日本医療薬学会年会, Sep. 2022.
42.	Kenta Yagi, 丸尾陽成, 石田俊介, 鍛治園誠, Fuka Aizawa, MIYATA Koji, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : ベバシズマブ治療継続にプロトンポンプ阻害剤，ボノプラザンが与える影響, 第32回日本医療薬学会年会, Sep. 2022.
43.	山川裕介, Kenta Yagi, Toshihiko Yoshioka, 佐藤真希, 丸尾陽成, MIYATA Koji, Fuka Aizawa, Yurika Kuniki, Takahiro Niimura, Satoshi Sakaguchi, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : 慢性骨髄性白血病患者における Bcr-Abl 阻害剤治療期間とアルコール摂取の関連, 第32回日本医療薬学会年会, Sep. 2022.
44.	Mitsuhiro Goda, Masaya Kanda, 吉岡俊彦, Takahiro Niimura, 櫻田巧, 小川敦, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 薬物療法の最適化を目指すリアルワールドデータ駆動型臨床薬理学研究, 第32回日本医療薬学会年会シンポジウム32, Sep. 2022.
45.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, SONODA Yuhei, Shimon Takahashi, Takahiro Niimura, Mitsuhiro Goda, Yoshito Zamami, Toshihiko Yoshioka, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 臨床薬理の視点で実践する創薬研究:抗がん剤有害事象をターゲットとしたトランスレーショナルリサーチ, 第32回日本医療薬学会年会シンポジウム55, Sep. 2022.
46.	Fuka Aizawa, Ami Okabayashi, Daishi Moriyama, SONODA Yuhei, Shimon Takahashi, NITTA Ayaka, Mitsuhiro Goda, Kenta Yagi, Takahiro Niimura, Yoshito Zamami, Yuki Izawa-Ishizawa and Keisuke Ishizawa : スタチンの pleiotropic effects: 抗がん剤誘発性末梢神経障害抑制作用の検討, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
47.	神田将哉, Mitsuhiro Goda, Toshihiko Yoshioka, 小川敦, 石田俊介, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータ解析を基盤としたシスプラチン誘発腎障害予防薬の探索, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
48.	Takashi Bandoh, Masayuki Chuma, Mitsuhiro Goda, Tomomi Tani, Yurika Kuniki, 小川敦, 櫻田巧, Fuka Aizawa, Takahiro Niimura, 八木健太, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータ解析および基礎研究を融合したバンコマイシン関連腎障害に対する予防薬探索, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
49.	MIYATA Koji, Yuki Izawa-Ishizawa, TSUJINAKA Kaito, Kohei Ohmine, Honoka Nishi, Shuto Itokazu, Takahiro Niimura, Masateru Kondoh, Fuka Aizawa, Hirofumi Hamano, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬に関連した動脈瘤・解離の病態解明, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
50.	Sayuri Itobayashi, Mitsuhiro Goda, Yugo Sugimoto, 石田朋奈, 神田将哉, Toshihiko Yoshioka, 小川敦, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : シスプラチン誘発急性腎障害に対するバルプロ酸ナトリウムの予防効果, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
51.	Yurika Kuniki, Kenta Yagi, Mayu Takaoka, OKAMOTO Naoki, Hirofumi Hamano, Fuka Aizawa, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 慢性骨髄性白血病に対する既存承認薬とALDH阻害剤併用の有効性, 次世代を担う若手のための創薬・医療薬理シンポジウム2022, Aug. 2022.
52.	Toshihiko Yoshioka, Mitsuhiro Goda, Sayuri Itobayashi, Yugo Sugimoto, Tomona Ishida, 神田将哉, 小川敦, 櫻田巧, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 薬剤性腎障害予防を志向したドラッグリポジショニング研究, 第31回霧島神経薬理フォーラム, Aug. 2022.
53.	MIYATA Koji, Yuki Izawa-Ishizawa, TSUJINAKA Kaito, Kohei Ohmine, Honoka Nishi, Shuto Itokazu, Takahiro Niimura, 近藤正輝, Fuka Aizawa, Hirofumi Hamano, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : 関連した動脈瘤・動脈解離:医療ビッグデータ解析と基礎薬理学実験によるアプローチ, 第29回市大フォーラム, Aug. 2022.
54.	Mitsuhiro Goda, 神田将哉, Toshihiko Yoshioka, Ami Yoshida, Sayuri Itobayashi, Takahiro Niimura, 櫻田巧, 小川敦, Naoto Okada, Fuka Aizawa, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 遺伝子発現および大規模医療情報データベースを活用したシスプラチン関連腎障害に対する予防薬の探索, 第51回日本心脈管作動物質学会学術集会, Jul. 2022.
55.	Sayuri Itobayashi, Mitsuhiro Goda, Ami Yoshida, Yugo Sugimoto, Masaya Kanda, Toshihiko Yoshioka, 櫻田巧, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 抗がん剤誘発急性腎障害に対するバルプロ酸ナトリウムの影響, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, Jul. 2022.
56.	Kenta Yagi, Mayu Takaoka, 丸尾陽成, Fuka Aizawa, Takahiro Niimura, Yuki Izawa-Ishizawa, Hirofumi Hamano, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : プロトンポンプ阻害剤，ボノプラザンが抗VEGF療法に与える影響, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, Jul. 2022.
57.	Yoshika Sakamoto, Nanami Tomochika, Takahiro Niimura, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Shiori Nishiuchi, 生田賢治, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータを活用したスニチニブ誘発心毒性に対する予防薬の探索, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, Jul. 2022.
58.	Kohei Ohmine, 近藤正輝, Mitsuhiro Goda, Honoka Nishi, MIYATA Koji, TSUJINAKA Kaito, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Keisuke Ishizawa and Yuki Izawa-Ishizawa : 大動脈瘤，解離に対する杜仲葉エキスの抑制効果の検討, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, Jul. 2022.
59.	Yurika Kuniki, Kenta Yagi, Mayu Takaoka, OKAMOTO Naoki, Hirofumi Hamano, Mitsuhiro Goda, Takahiro Niimura, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 慢性骨髄性白血病に対するBCR-ABL阻害剤とALDH阻害剤併用による抗腫瘍効果増強の検討, 医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム, Jul. 2022.
60.	MIYATA Koji, Yuki Izawa-Ishizawa, 近藤正輝, TSUJINAKA Kaito, Kohei Ohmine, 西穂香, Shuto Itokazu, Takahiro Niimura, Fuka Aizawa, Hirofumi Hamano, Kenta Yagi, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : フルオロキノロン系抗菌薬による血管毒性の病態解明, 第141回日本薬理学会近畿部会, Jul. 2022.
61.	Hiroto Unten, Hirofumi Hamano, Takahiro Niimura, Kazushi Uchida, Nanami Tomochika, MIYATA Koji, 石田俊介, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yoshito Zamami and Keisuke Ishizawa : 免疫チェックポイント阻害剤関連心筋炎の解析に適した実験的病態モデルの開発, 第141回日本薬理学会近畿部会, Jul. 2022.
62.	Rie Andou, Kenta Yagi, OKAMOTO Naoki, Mayu Takaoka, Fuka Aizawa, Hirofumi Hamano, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : 各種プロトンポンプ阻害剤のがん細胞におけるVEGF発現に与える影響, 日本薬学会第142年会, Mar. 2022.
63.	Sayuri Itobayashi, Mitsuhiro Goda, Ami Yoshida, Yugo Sugimoto, Masaya Kanda, Toshihiko Yoshioka, 櫻田巧, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの有効性の検証, 日本薬学会第142年会, Mar. 2022. (Keyword) data analysis / kidney disease
64.	Fuka Aizawa, Haruna Kajimoto, Daishi Moriyama, Ami Okabayashi, Mitsuhiro Goda, Hirofumi Hamano, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : リアルワールドデータに基づく抗がん剤支持療法の開発;スタチン系薬剤による末梢神経障害治療および予防効果の検証, 第95回日本薬理学会年会, Mar. 2022. (Keyword) data analysis
65.	Toshihiko Yoshioka, Mitsuhiro Goda, Masaya Kanda, Ami Yoshida, Sayuri Itobayashi, Yugo Sugimoto, Yuki Izawa-Ishizawa, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Yoshito Zamami and Keisuke Ishizawa : シスプラチン誘発急性腎障害に対するバルプロ酸ナトリウムの影響, 第95回日本薬理学会年会, Mar. 2022. (Keyword) data analysis / kidney disease
66.	MIYATA Koji, Yuki Izawa-Ishizawa, Masateru Kondoh, TSUJINAKA Kaito, Kohei Ohmine, Honoka Nishi, Fuka Aizawa, Hirofumi Hamano, Yoshito Zamami, Mitsuhiro Goda and Keisuke Ishizawa : 杜仲葉エキスによる大動脈解離発症抑制効果の検討, 第95回日本薬理学会年会, Mar. 2022.
67.	Yoshika Sakamoto, Nanami Tomochika, Hirofumi Hamano, Mitsuhiro Goda, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Akihito Nakamura, Shiori Nishiuchi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 大規模医療情報データベースを用いたスニチニブ誘発心不全に対する予防薬の探索, 第95回日本薬理学会年会, Mar. 2022.
68.	Yurika Kuniki, Kenta Yagi, Rina Yoshida, OKAMOTO Naoki, Rie Andou, 山川裕介, Hirofumi Hamano, Mitsuhiro Goda, Takahiro Niimura, Fuka Aizawa, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 慢性骨髄性白血病に対するBCR-ABL阻害剤とALDH阻害剤併用による抗腫瘍効果, 第95回日本薬理学会年会, Mar. 2022.
69.	Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Takahiro Niimura, 櫻田巧, 小川敦, Naoto Okada, Fuka Aizawa, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータ解析と基礎研究を融合した研究手法による抗がん剤誘発副作用に対する予防法の探索, 日本臨床腫瘍薬学会学術大会2022 シンポジウム 12, Mar. 2022. (Keyword) data analysis
70.	Shiori Nishiuchi, Hiroumi Saito, Takahiro Niimura, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yuki Izawa-Ishizawa and Keisuke Ishizawa : ドキソルビシン誘発心筋症に対する予防薬探索を目的としたドラッグリポジショニング研究, 第42回日本臨床薬理学会学術総会, Dec. 2021.
71.	Rie Andou, Kenta Yagi, OKAMOTO Naoki, Fuka Aizawa, Hirofumi Hamano, Yuki Izawa-Ishizawa, Mitsuhiro Goda, Yoshito Zamami and Keisuke Ishizawa : ボノプラザンががん細胞のVEGF発現に与える影響に関する検討, 第140回日本薬理学会近畿部会, Nov. 2021.
72.	Ami Yoshida, Mitsuhiro Goda, Yugo Sugimoto, Hikari Yagita, Masaya Kanda, Toshihiko Yoshioka, 櫻田巧, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : シスプラチン誘発腎障害に対する新規予防候補薬の効果, 第140回日本薬理学会近畿部会, Nov. 2021. (Keyword) kidney disease / data analysis
73.	Kohei Ohmine, Masateru Kondoh, Mitsuhiro Goda, Honoka Nishi, MIYATA Koji, TSUJINAKA Kaito, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yoshito Zamami, Keisuke Ishizawa and Yuki Izawa-Ishizawa : 杜仲茶エキスによる大動脈疾患発症抑制効果の検討, 第140回日本薬理学会近畿部会, Nov. 2021.
74.	Naoto Okada, Aki Nakamoto, 泉侑希, Masayuki Chuma, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa : タゾバクタム・ピペラシリン併用時における血中濃度時間曲線下面積に基づくバンコマイシン誘発腎障害の評価, 第15回日本腎臓病薬物療法学会学術集会・総会2021, Nov. 2021.
75.	Toshihiko Yoshioka, Mitsuhiro Goda, Masaya Kanda, Ami Yoshida, Sayuri Itobayashi, Yugo Sugimoto, Yuki Izawa-Ishizawa, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Yoshito Zamami and Keisuke Ishizawa : シスプラチン誘発腎障害に対する杜仲葉エキスの効果, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) kidney disease / data analysis
76.	Ami Yoshida, Mitsuhiro Goda, Yugo Sugimoto, Hikari Yagita, Masaya Kanda, Toshihiko Yoshioka, Takumi Sakurada, Yuki Izawa-Ishizawa, Fuka Aizawa, Hirofumi Hamano, Naoto Okada, Kenta Yagi, Yoshito Zamami and Keisuke Ishizawa : シスプラチン誘発腎障害に対する新規予防薬の探索, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) data analysis / kidney disease
77.	Tomomi Tani, Masayuki Chuma, Mitsuhiro Goda, Takashi Bandoh, Masateru Kondoh, Yurika Kuniki, Hirofumi Hamano, Takahiro Niimura, Naoto Okada, Fuka Aizawa, Kenta Yagi and Keisuke Ishizawa : ビッグデータ解析を活用したバンコマイシン関連腎障害に対する予防薬の探索とその有用性の検討, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) data analysis
78.	Haruna Kajimoto, Daishi Moriyama, Fuka Aizawa, Takahiro Niimura, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa and Keisuke Ishizawa : FAERS解析を活用したオキサリプラチン誘発末梢神経障害に対する予防薬の検討, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) data analysis
79.	Shimon Takahashi, Kenshi Takechi, JOHZUKURI Natsumi, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 大規模医療情報データベースを用いたドラッグリポジショニングによるバラシクロビルの抗てんかん作用の検討, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) data analysis
80.	Hiroto Unten, Hirofumi Hamano, Takahiro Niimura, Nanami Tomochika, Shiori Nishiuchi, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Yoshito Zamami and Keisuke Ishizawa : Exploration of prophylactic drugs against doxorubicin-induced cardiomyopathy using largescale medical databases, 第15回次世代を担う若手のための医療薬科学シンポジウム, Oct. 2021.
81.	TSUJINAKA Kaito, Naoto Okada, 藤原範子, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, 櫻田巧, 桐野靖, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa : 医療従事者におけるインフルエンザ暴露後予防目的におけるオセルタミビルのアドヒアランス解析, 第31回日本医療薬学会年会, Oct. 2021.
82.	Naoto Okada, Aki Nakamoto, 泉侑希, Masayuki Chuma, Mitsuhiro Goda, Kenta Yagi, Fuka Aizawa, Hirofumi Hamano, Yoshito Zamami, Momoyo Azuma and Keisuke Ishizawa : タゾバクタム・ピペラシリン併用時のバンコマイシン誘発腎障害は血中濃度時間曲線下面積を指標とした TDMによって回避可能か?, 第31回日本医療薬学会年会, Oct. 2021.
83.	Fuka Aizawa, Haruna Kajimoto, Daishi Moriyama, Takahiro Niimura, Mitsuhiro Goda, NITTA Ayaka, Shimon Takahashi, Hirofumi Hamano, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 医療ビッグデータを基盤とした迅速かつ安全ながん支持療法の開発, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis
84.	Yoshito Zamami, Takahiro Niimura, Hirofumi Hamano, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : リアルワールドデータを活用したドラッグリポジショニング研究, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis
85.	Hirofumi Hamano, Yoshito Zamami, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi and Keisuke Ishizawa : データサイエンスと基礎研究手法の融合, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis
86.	Masayuki Chuma, Aki Nakamoto, Takashi Bandoh, Takahiro Niimura, Naoto Okada, Fuka Aizawa, Hirofumi Hamano, Kenta Yagi, Mitsuhiro Goda, Yoshito Zamami, Keisuke Ishizawa and Yoshikazu Tasaki : メタアナリシスとデータベース解析の融合によるハイインパクトエビデンスの創出, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis
87.	Masaya Kanda, Mitsuhiro Goda, Toshihiko Yoshioka, Ami Yoshida, Takahiro Niimura, Takumi Sakurada, Atsushi Ogawa, Naoto Okada, Fuka Aizawa, Yoshito Zamami, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 抗がん剤副作用予防のための大規模医療情報データベース解析を活用したリバーストランスレーショナルリサーチ, 第31回日本医療薬学会年会, Oct. 2021. (Keyword) data analysis / kidney disease
88.	Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Ami Yoshida, Takahiro Niimura, Takumi Sakurada, Atsushi Ogawa, Naoto Okada, Fuka Aizawa, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 大規模医療情報データベースを活用した抗がん剤副作用に対する予防法の確立, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2021. (Keyword) data analysis / kidney disease
89.	TSUJINAKA Kaito, Yuki Izawa-Ishizawa, Takahiro Niimura, Toshihiko Yoshioka, Mitsuhiro Goda, Masateru Kondoh, Kohei Ohmine, Honoka Nishi, MIYATA Koji, Hirofumi Hamano, Fuka Aizawa, Kenta Yagi, Yoshito Zamami and Keisuke Ishizawa : 血管新生阻害剤における大動脈解離発症の関連要因解明, 第50回日本心脈管作動物質学会, Jul. 2021.
90.	Haruna Kajimoto, Daishi Moriyama, Fuka Aizawa, Takahiro Niimura, Yoshito Zamami, Mitsuhiro Goda, Kenta Yagi, Hirofumi Hamano, Yuki Izawa-Ishizawa and Keisuke Ishizawa : オキサリプラチン誘発末梢神経障害に対するスタチン系薬剤の予防効果, 第139回日本薬理学会近畿部, Jun. 2021. (Keyword) data analysis / kidney disease
91.	Tomomi Tani, Masayuki Chuma, Mitsuhiro Goda, Takashi Bandoh, Masateru Kondoh, Yurika Kuniki, Hirofumi Hamano, Takahiro Niimura, Naoto Okada, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami and Keisuke Ishizawa : 大規模医療情報および遺伝子発現データベースを活用したバンコマイシン関連腎障害に対する予防薬の探索とソの有用性の検討, 第139回日本薬理学会近畿部, Jun. 2021. (Keyword) data analysis / kidney disease
92.	Fuka Aizawa, Yoshito Zamami, Takahiro Niimura, Takehiro Kawashiri, Mitsuhiro Goda, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : HMG-CoA還元酵素阻害剤はGSTを介してオキサリプラチン誘発末梢神経障害を抑制する, 第94回日本薬理学会年会, Mar. 2021.
93.	Takahiro Niimura, Yoshito Zamami, 川尻雄大, Mitsuhiro Goda, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 基礎研究と臨床研究の融合による薬剤性末梢神経障害に対する予防薬探索, 日本薬学会第141年会, Mar. 2021. (Keyword) data analysis
94.	Fuka Aizawa, Yoshito Zamami, Hirofumi Hamano, Naoto Okada, 林明希, Kenta Yagi, Mitsuhiro Goda, 桐野靖, 中村敏己 and Keisuke Ishizawa : COVID-19感染拡大に伴うオンライン型薬学実務実習の導入, 日本薬学会第141年会, Mar. 2021.
95.	Fuka Aizawa, Haruna Kajimoto, Daishi Moriyama, Takahiro Niimura, Yoshito Zamami, Hirofumi Hamano, Mitsuhiro Goda, Kenta Yagi, Yuki Izawa-Ishizawa and Keisuke Ishizawa : オキサリプラチン誘発末梢神経障害に対するHMG-CoA還元酵素阻害剤の影響, 第262回徳島医学会学術集会, Mar. 2021.
96.	Mitsuhiro Goda, Yoshito Zamami, Takahiro Niimura, 萱野純史, Hirofumi Hamano, Naoto Okada, Fuka Aizawa, Kenta Yagi, Yuki Izawa-Ishizawa, 桐野靖, 中村敏己 and Keisuke Ishizawa : 大規模医療情報データベースを活用した抗がん剤副作用予防のためのリバーストランスレーショナルリサーチ, 日本薬学会第140年会, Mar. 2021.
97.	Yoshika Sakamoto, Yoshito Zamami, Takahiro Niimura, Fuka Aizawa, Kenta Yagi, Mitsuhiro Goda, Yuki Izawa-Ishizawa and Keisuke Ishizawa : 大規模医療情報データベースを用いたドキソルビシン誘発心筋症に対する予防薬の探索, 日本薬学会第141年会大学院生・学生シンポジウム, Mar. 2021. (Keyword) data analysis
98.	Fuka Aizawa, Mitsuhiro Goda, Masaya Kanda, Toshihiko Yoshioka, Ami Yoshida, Takahiro Niimura, Kenta Yagi, Hirofumi Hamano, Naoto Okada, Yoshito Zamami, Yuki Izawa-Ishizawa and Keisuke Ishizawa : シスプラチンと5-HT3受容体拮抗薬併用が腎機能障害に与える影響, 第30回日本循環薬理学会, Nov. 2020.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

リアルワールドデータを活用した薬剤性腎障害に対する新規予防戦略の開発 (Project/Area Number: 23K06234 )
MDB活用による抗がん剤誘発性末梢神経障害予防薬の確立 (Project/Area Number: 22K15292 )
Gendered innovation in cancer chemotherapy - real world data driven pharmacological research (Project/Area Number: 22K06863 )
Elucidation of the relationship between infectious diseases and aortic diseases by big data analysis and in vivo experiments (Project/Area Number: 21H02646 )
Development of an Evaluation System for Synergistic Effects and Pharmacological Verification (Project/Area Number: 20H05799 )
Development of a Novel Chemotherapy-Induced Peripheral Neuropathy Prevention Strategy by Applying Real World Data (Project/Area Number: 20K16007 )
Search by Researcher Number (80848367)

Designated Assistant Professor : Aizawa, Fuka

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Letter:

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)